Cliffwater LLC Takes $667,000 Position in Tempus AI, Inc. $TEM

Key Points

• Cliffwater LLC acquired a new stake in Tempus AI, Inc., purchasing 13,824 shares valued at approximately $667,000, making it the firm’s 15th largest investment.
• Recent insider sales included Director Jennifer A. Doudna selling 625 shares and Director Theodore Leonsis selling 44,000 shares of Tempus AI stock, indicating significant changes in ownership among executives.
• Equities analysts have issued varying ratings and have been adjusting price targets, with Bank of America raising its target for Tempus AI from $68.00 to $70.00 and others setting targets between $60.00 and $75.00.

Cliffwater LLC bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 13,824 shares of the company's stock, valued at approximately $667,000. Tempus AI makes up 0.2% of Cliffwater LLC's holdings, making the stock its 15th largest position.

A number of other hedge funds have also recently modified their holdings of the business. First Horizon Advisors Inc. boosted its stake in Tempus AI by 12.7% in the 1st quarter. First Horizon Advisors Inc. now owns 1,849 shares of the company's stock worth $89,000 after purchasing an additional 208 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Tempus AI by 13.2% in the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company's stock worth $80,000 after purchasing an additional 278 shares in the last quarter. Bartlett & CO. Wealth Management LLC boosted its stake in Tempus AI by 100.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company's stock worth $39,000 after purchasing an additional 400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Tempus AI by 10.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,594 shares of the company's stock worth $268,000 after purchasing an additional 515 shares in the last quarter. Finally, Cherry Tree Wealth Management LLC bought a new position in Tempus AI in the 1st quarter worth about $31,000. Institutional investors own 24.22% of the company's stock.

Insider Activity

In other news, Director Jennifer A. Doudna sold 625 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $62.52, for a total transaction of $39,075.00. Following the completion of the sale, the director owned 26,554 shares of the company's stock, valued at $1,660,156.08. This represents a 2.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Theodore Leonsis sold 44,000 shares of the company's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $69.90, for a total transaction of $3,075,600.00. Following the sale, the director directly owned 86,756 shares of the company's stock, valued at $6,064,244.40. The trade was a 33.65% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 802,772 shares of company stock worth $54,080,775. Company insiders own 27.60% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on TEM shares. Bank of America upped their price target on shares of Tempus AI from $68.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 25th. BTIG Research assumed coverage on shares of Tempus AI in a research note on Friday, August 8th. They issued a "buy" rating and a $60.00 price target on the stock. Needham & Company LLC restated a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research note on Friday, August 8th. Piper Sandler reiterated a "neutral" rating on shares of Tempus AI in a research note on Friday, August 8th. Finally, Guggenheim lifted their price target on shares of Tempus AI from $65.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, June 30th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $65.36.

Tempus AI Stock Performance

Shares of TEM stock opened at $73.78 on Monday. The company has a 50 day moving average price of $63.13 and a 200-day moving average price of $58.64. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $91.45. The firm has a market capitalization of $12.82 billion, a PE ratio of -62.00 and a beta of 4.98. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The firm had revenue of $314.64 million during the quarter, compared to analyst estimates of $296.84 million. During the same quarter in the prior year, the firm earned ($6.86) EPS. The business's revenue for the quarter was up 89.5% compared to the same quarter last year. As a group, equities research analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.